Latest News and Press Releases
Want to stay updated on the latest news?
-
BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors,...
-
Tevogen reports 2025 progress advancing its scalable ExacTcell platform, expanding multi-indication CTL programs, and strengthening manufacturing readiness
-
2026 soll für BioNTech ein Jahr mit zahlreichen wertrelevanten Meilensteinen (Katalysatoren) werden, unter anderem durch weitere Fortschritte bei Pipeline-Kandidaten, die sich bereits in der späten...
-
2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026...
-
New capabilities enable Teladoc Health’s care teams to address a broader spectrum of health needs, delivering more value in virtual urgent care visits
-
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech...
-
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative...
-
Defiance Launches JPX: The First 2X Leveraged ETF on JPM (JP Morgan)